
In 2026, the Fontan procedure remains the definitive surgical solution for children born with single-ventricle heart defects (such as Hypoplastic Left Heart Syndrome). It is the final stage of a three-part surgical journey designed to allow one ventricle to do the work of two.
Diagnosis of Hypoplastic Left Heart Syndrome (HLHS)
Presence of Tricuspid Atresia or other single-ventricle defects
Completion of the Glenn procedure (the previous surgical stage)
Low oxygen saturation levels (cyanosis) causing a bluish tint to skin
Age-appropriate milestones, typically between ages 2 and 5
Redirecting oxygen-poor blood from the lower body directly to the lungs
Bypassing the heart to prevent the mixing of rich and poor blood
Reducing the long-term workload and strain on the single ventricle
Improving systemic oxygen levels throughout the entire body
Enhancing the child's physical stamina and overall growth potential
Connection: The inferior vena cava (IVC) is connected directly to the pulmonary artery.
Conduit Placement: A synthetic tube (extracardiac conduit) is used to complete the path.
Fenestration: A tiny "relief valve" hole is often created to help the lungs adjust.
3D Modeling: Surgeons use 3D-printed replicas to pre-plan the exact conduit fit.
Circulation: The heart-lung machine supports the body while the "re-plumbing" occurs.
3D-Printed Modeling: Custom replicas allow for "test-run" surgery planning.
Virtual Reality (VR): Teams virtually navigate the chest to ensure efficient blood flow.
Hybrid Procedures: Select cases allow for catheter-based completions in the lab.
Hemodynamic Mapping: Advanced imaging ensures the most efficient flow patterns.
Biocompatible Materials: Newer conduit materials reduce the risk of clot formation.
Hospital Stay: Patients typically stay for 1 to 2 weeks for pressure monitoring.
Home Monitoring: Wearable sensors track oxygen and fluid retention in real-time.
Activity: A gradual return to play is encouraged as the new circulation stabilizes.
Lifelong Care: Requires ongoing follow-up at specialized Congenital Heart clinics.
Transition: Long-term management evolves into Adult Congenital Heart Disease (ACHD) care.
Structural vs. Functional: Tumor removal exits a mass; Fontan re-plumbs the system.
Surgical Scope: Both utilize 2026 robotic and imaging tools for high safety margins.
Treatment Path: Tumor surgery is often a single event; Fontan is part of a multi-stage journey.
Outcome Goals: Both aim to restore heart efficiency and improve quality of life.
Monitoring: Both require expert cardiology follow-up to ensure long-term success.
Significant increase in blood oxygenation and reduction in "blue" symptoms
Protects the single ventricle from premature failure or overwork
Allows children to participate more fully in physical and social activities
Utilizes the latest 2026 synthetic materials for better long-term durability
Provides a clear pathway for transition into healthy adulthood